Identification of residues in the drug-binding domain of human P-glycoprotein - Analysis of transmembrane segment 11 by cysteine-scanning mutagenesisand inhibition by dibromobimane

The drug-binding domain of the human multidrug resistance P-glycoprotein (P -gp) probably consists of residues from multiple transmembrane (TM) segment s. In this study, we tested whether the amino acids in TM11 participate in binding drug substrates, Each residue in TM11 was initially altered by site -directed mutagenesis and assayed for drug-stimulated ATPase activity in th e presence of verapamil, vinblastine, or colchicine, Mutants G939V, F942A, T945A, Q946A, A947L, Y953A, A954L, and G955V had altered drug-stimulated AT Pase activities. Direct evidence for binding of drug substrate was then det ermined by cysteine-scanning mutagenesis of the residues in TM11 and inhibi tion of drug-stimulated ATPase activity by dibromobimane, a thiol-reactive substrate. Dibromobimane inhibited the drug-stimulated ATPase activities of two mutants, F942C and T945C, by more than 75%, These results suggest that residues Phe(942) and Thr(945) in TM11, together with residues previously identified in TM6 (Leu(339) and Ala(342)) and TM12 (Leu(975), Val(982), and Ala(985)) (Loo, T. W., and Clarke, D. M. (1997) J. Biol. Chem. 272, 31945- 31948) form part of the drug-binding domain of P-gp.